March 05, 2018
Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial
In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
-
The Department of Defense’s Breakthrough Nuclear Moment Risks Slipping Away
Commentary
Unless they act, the Department of Defense’s breakthrough nuclear moment may vanish before it really happens....
By Will Rogers
-
DEFAERO Strategy Series [Apr 09, 25] CNAS' Becca Wasser and Phil Sheers on Revitalizing the U.S. Defense Industrial Base
Podcast
On this episode of the Defense & Aerospace Report Strategy Series, sponsored by General Atomics Aeronautical Systems, Becca Wasser and Phil Sheers of the Center for a New Amer...
By Becca Wasser & Philip Sheers
-
From Production Lines to Front Lines
Reports
Executive Summary The U.S. defense industrial base (DIB) is struggling to meet the demands of the current strategic environment—let alone prepare for a potential conflict agai...
By Becca Wasser & Philip Sheers
-
The Pentagon’s Endangered Brain Trust
Commentary
In this environment, sound assessments of emerging threats and new ideas to counter them will be especially vital....
By Dr. Andrew Krepinevich, Jr.
